Jubilant Pharmova Share Price Falls Over 4% After Q3 FY26 Earnings, Net Profit Drops 17%

Jubilant Pharmova share price (NSE: JUBLPHARMA) dropped more than 4% on Friday after the company reported lower profit for Q3 FY26. The stock touched an intraday low near ₹931 and was later trading around ₹938, down compared with a largely flat Nifty 50.

Over the past one year, the stock has fallen about 8%, while the benchmark index has gained roughly 8.5%.

Profit Falls Due to Exceptional Losses

The company’s normalised profit after tax (PAT) declined 17% year-on-year to ₹86 crore in the December quarter, compared with ₹104 crore a year earlier. The PAT margin also reduced to 4% from 5.7%.

This drop was mainly caused by:

• An exceptional loss of ₹13 crore linked to labour code changes
• A ₹26 crore loss due to temporary suspension of manufacturing at the Montreal CDMO sterile injectables facility

Revenue Growth but Margin Pressure

Despite the profit decline, the company reported strong operating growth:

• Revenue rose 17% YoY to ₹2,123 crore, supported by good performance across segments, especially CDMO sterile injectables.
• EBITDA increased 5% YoY to ₹310 crore, but the EBITDA margin fell to 14.5% from 16.2%, showing pressure on profitability.

Management Outlook

Management expects the growth trend to continue in Q4 FY26, helped by:

• Higher revenue from technology transfer programs in the CDMO segment
• Continued investment in CRDMO capabilities
• Expected improvement in the generics business

Also Read: REC Dividend Record Date on February 06: Interim Dividend of ₹4.60!

Conclusion

Jubilant Pharmova delivered strong revenue growth in Q3, but exceptional losses and weaker margins reduced profit and weighed on the share price. Future movement will depend on margin recovery and continued business growth.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.